Ask AI
ProCE Banner Activity

Phase IIb MK-8591B-060: Switch to Once-Weekly Islatravir + Ulonivirine in Adults With Virologically Suppressed HIV

Conference Coverage
Slideset

In the open-label phase IIb MK-8591B-060 trial conducted in people with stable virological suppression on daily BIC/FTC/TAF, switching to once-weekly islatravir (ISL) plus investigational ulonivirine (ULO) maintained HIV-1 RNA <50 copies/mL through Week 24. ISL plus ULO was well tolerated and showed no new safety signals.

Released: July 31, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Partners

International AIDS Society

ProCE Banner

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions